A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS)

Journals

1. Kuwahara M, Kusunoki S. Mechanism and spectrum of anti‐glycolipid antibody‐mediated chronic inflammatory demyelinating polyneuropathy. Clinical and Experimental Neuroimmunology 2018;9(1):65 View
2. Misawa S, Suichi T. Guillain‐Barré syndrome: Novel treatment by complement inhibition. Clinical and Experimental Neuroimmunology 2020;11(2):90 View
3. Uncini A, Vallat J. Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground. Journal of Neurology, Neurosurgery & Psychiatry 2018;89(6):627 View
4. Liu S, Dong C, Ubogu E. Immunotherapy of Guillain-Barré syndrome. Human Vaccines & Immunotherapeutics 2018:1 View
5. Keller C, Quast I, Dalakas M, Lünemann J. IVIG efficacy in CIDP patients is not associated with terminal complement inhibition. Journal of Neuroimmunology 2019;330:23 View
6. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, Nagashima T, Shimizu T, Hirotani M, Kadoya M, Nakahara J, Shimizu J, Tanaka M, Sobue G, Katsuno M, Yamaguchi H, Ogata H. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. The Lancet Neurology 2018;17(6):519 View
7. Doets A, Hughes R, Brassington R, Hadden R, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2020;2020(1) View
8. Pilch K, Spaeth P, Yuki N, Wakerley B. Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. Expert Review of Neurotherapeutics 2017;17(6):579 View
9. Yamagishi Y, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida K, Ikeda S, Mutoh T, Yamasaki R, Takashima H, Matsui M, Nishiyama K, Sobue G, Kusunoki S. Markers for Guillain‐Barré syndrome with poor prognosis: a multi‐center study. Journal of the Peripheral Nervous System 2017;22(4):433 View
10. Wijdicks E, Klein C. Guillain-Barré Syndrome. Mayo Clinic Proceedings 2017;92(3):467 View
11. Misawa S. Development of new treatments with drug repositioning strategies: POEMS and Guillain‐Barré syndrome. Neurology and Clinical Neuroscience 2021;9(1):50 View
12. Briani C, Visentin A. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies. Neurotherapeutics 2022;19(3):874 View
13. Momenzadeh S, Jami M. Remyelination in PNS and CNS: current and upcoming cellular and molecular strategies to treat disabling neuropathies. Molecular Biology Reports 2021;48(12):8097 View
14. Rajabally Y. Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome. Neurotherapeutics 2022;19(3):885 View
15. Masakado Y. Recent Advances in Diagnosis and Therapy of Peripheral Neuropathy. The Japanese Journal of Rehabilitation Medicine 2023;60(3):184 View
16. Antoine J. Antibodies in immune-mediated peripheral neuropathies. Where are we in 2024?. Revue Neurologique 2024;180(9):876 View

Books/Policy Documents

1. Yadav N, Pragati , Dwivedi M. Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases. View
2. El-Abassi R, Soliman M, Levy M, England J. Neuromuscular Disorders. View